Study of Adebrelimab With or Without Chemotherapy Followed by Chemoradiotherapy for Advanced Esophageal Squamous Cell Carcinoma

What this Trial Is About

Researchers are evaluating how well adebrelimab, with or without induction chemotherapy, works when followed by concurrent chemoradiotherapy for people with unresectable locally advanced esophageal squamous cell carcinoma. This phase 2 trial divides participants into two groups based on their CPS scores to better understand treatment effects and safety. Participants with a CPS score of 10 or higher receive induction therapy with adebrelimab alone, given intravenously every three weeks for two cycles over six weeks. Those with CPS scores below 10 receive adebrelimab combined with chemotherapy drugs carboplatin or cisplatin and paclitaxel or nab-paclitaxel, also over two cycles in six weeks. Both groups then receive concurrent chemoradiotherapy including carboplatin or cisplatin and paclitaxel or nab-paclitaxel weekly for five weeks alongside 50Gy radiotherapy delivered in 25 fractions. During the study, participants undergo assessments to measure complete clinical response up to six months after treatment starts. Researchers also track overall survival, progression-free survival, response rates, duration of response, disease control rate, radiotherapy completion, and adverse events over various time frames up to five years. The study involves regular monitoring and follow-up visits to evaluate treatment effects and safety in adults aged 18 to 70 years with this form of esophageal cancer.

Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC